Follitropin Beta

Summary

Follitropin Beta (CHEMBL5315126) is an approved protein (ATC G03GA06); indicated across 2 conditions including infertility disorder and hypogonadism.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: G03GA06
• Indications: 2 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315126
Name	Follitropin Beta
Type	Protein
Max phase	4
ATC	G03GA06

Also known as: Fertavid, Folitropina beta, Follitropin beta, Follitropine beta, Puregon, FOLLITROPIN BETA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
infertility disorder	4	MONDO:0005047	EFO:0000545
hypogonadism	4	MONDO:0002146	HP:0000044

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
Not specified	7
PHASE4	6
PHASE3	4
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00225433	PHASE4	COMPLETED	Luteal Phase FSH in the IVF Poor Responder
NCT00802360	PHASE4	COMPLETED	MENOPUR® Versus FOLLISTIM®
NCT00805935	PHASE4	COMPLETED	Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
NCT02466204	PHASE4	COMPLETED	Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients
NCT02471677	PHASE4	UNKNOWN	Corifollitropin Alfa Versus Follitropin Beta in High Responders
NCT04695483	PHASE4	COMPLETED	Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial
NCT00696800	PHASE3	COMPLETED	A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
NCT01144416	PHASE3	COMPLETED	Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)
NCT03197077	PHASE3	COMPLETED	Optimisation of Follicular Recruitment in IVM Cycles
NCT03228680	PHASE3	COMPLETED	Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women
NCT02309671	PHASE2	COMPLETED	A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment
NCT00702273	Not specified	COMPLETED	Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
NCT00703014	Not specified	COMPLETED	Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
NCT00920361	Not specified	COMPLETED	Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)
NCT00920634	Not specified	COMPLETED	Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)
NCT01882166	Not specified	TERMINATED	Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment
NCT02635607	Not specified	UNKNOWN	Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol
NCT04142190	Not specified	COMPLETED	Corifollitropin Alfa and Embryo Morphokinetics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).